Crystal Ball Cloudy for PI3K Inhibitors' Future in Hematology
MedPage Today reported on developments leading to PI3K inhibitors losing multiple indications over safety and efficacy concerns. In this report, we outline what to expect in the coming year. The PI3K inhibitor drug class had a rough go of it in the regulatory realm during 2022.
Monday, January 2, 2023 at 9:04 pm